Institutional investors hold a majority ownership of ALXN through the 96.96% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended September 2017, these large investors purchased a net $52.5 thousand shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
JENNISON ASSOCIATES LLC Bought 4.7 Million shares of Alexion Pharmaceuticals I...
ASSENAGON ASSET MANAGEMENT SA (G... Bought 865.0 Thousand shares of Alexion Pharmaceuticals I...